Member Info for itshenderz

Lots of good chat here, but it's still important to focus on the drug and why we think it'll work also.

Here's another article expressing interferon 1b.

https://www.news-medical.net/amp/news/20200522/Study-evaluates-the-effectiveness-of-interferon-beta-1b-in-COVID-19-pneumonia.aspx

DubleD- Come back in a few months.

Enough said.

Any spike will get sold heavily into unfortunately. People will look to break even and get out, only thing that will keep this up to previous support of 50/60p is the delivery off positive news or a holdings statement to say lansdowne have sold their lot. Fundamentals haven't changed.

Keep calm and carry on.

All imvho.

She's moving fast on L2

Now if anyone knew that they'd be a very rich man, let me get my crystal ball out and ill get back to you.

notnow20 - With you all the way.

Hindsight is a beautiful thing, if I knew when was the right/wrong time to buy id be a millionaire.

I see lots of private investors on this board are questioning their initial investment and perhaps doubting the research they've done, mainly due to the price action. Let me just say, fear lines the pocket of the rich. A good quote from Warren Buffet "be greedy when others are fearful, be fearful when others are greed". Yes the price action in the last few weeks has been poor, I totally agree, but in this game its the 'big boys' the 'majors' whatever you want to call them that will prosper 99% of the time on the back of your actions. What I'm getting at is don't panic sell or panic buy due small price actions which is manipulated to benefit no.1 and no.1 only. I'm not saying to just hold knowing the outcome will be positive, because it can go either way, and I'll hold my hands up and admit I got it wrong if it ends up being a flop. But never will I give up hard earned money to line the pockets of the few due to scare tactics and mongering. The wise amongst you will know what I'm saying but perhaps new investors (most venerable) will not, and its useful to do your research on not only the share, but the platform you're trading it on with.

All imvho ofcourse.

Dyor.

You could say I'm being biased as I'm invested here, but I genuinely do see a slow rise from here, and perhaps a few surprises along the way. COPD results, update on hospital/home trials, any of which could see strength added. Too risky to play imo, but I guess everyone wants the next 'big riser' today.... ill be holding my shares way all the way until results on all plays are delivered, and for that I believe I and many others will be rewarded. Switch off LSE board for a few days or if not weeks (easier said than done I know) and refresh yourself on why you're invested.

Goodluck.

All imvho.

Dyor.

Moving up on L2, let's see the where the moneys at folks.

Hypothetically speaking, but all it takes is an rns stating home trial recruitment's are progressing better than expected, and watch everyone flock back in.... to much can happen here in a short time.

'Covid19 is dying out' ... the peak may have settled down, but there's still 1/2 thousands covid related new cases a day in the UK alone. Today a surge in South Korea (mainly due to nightclubs reopening) in Seoul. South America and USA still severely suffering. Can you say that a 2nd peak won't hit here once reopening? Probably not.

Totally agree and see why investors are getting paid annoyed, only takes a 10-15% rise one day and everyone's back to posting how its '£1 next week' swings and roundabouts.

Sure does, looks another poor morning....

Realistically, on the chance both results are entirely different, they can justify and go into detail as to why. Wouldn't promote the company releasing singular news articles with 2 opposite outcomes.

Just my opinion.

Lots of positives here, however, is the home trial a bit too ambitious? Discuss...

Wouldn't be surprised to see a tr-1 today.

L2 looks poised and ready for a tick up ;-)

Speaks for itself...

“Over the coming months we
will have three major clinical trial read-outs for SNG001, our wholly-owned, inhaled
IFN-beta asset: COPD patients with regular seasonal viruses; COVID-19 hospital-
treated patients; and the early treatment of COVID-19 patients in the home setting.
The Company is active on many fronts from designing and managing novel trials to
developing the regulatory strategy and supply chain for potential demand in the future.”

Bounced hard, 50s back on.